ATE329894T1 - Verwendung von cyclopropancyclus enthaltenden carbonsäureverbindungen als medikament - Google Patents
Verwendung von cyclopropancyclus enthaltenden carbonsäureverbindungen als medikamentInfo
- Publication number
- ATE329894T1 ATE329894T1 AT01271349T AT01271349T ATE329894T1 AT E329894 T1 ATE329894 T1 AT E329894T1 AT 01271349 T AT01271349 T AT 01271349T AT 01271349 T AT01271349 T AT 01271349T AT E329894 T1 ATE329894 T1 AT E329894T1
- Authority
- AT
- Austria
- Prior art keywords
- potentiation
- ltp
- synaptic transmission
- cyclopropancyclus
- medication
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title 1
- 230000005062 synaptic transmission Effects 0.000 abstract 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 2
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical group C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000020358 Learning disease Diseases 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- -1 carboxylic acid compound Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 201000003723 learning disability Diseases 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 230000003957 neurotransmitter release Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C61/04—Saturated compounds having a carboxyl group bound to a three or four-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/132—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings
- C07C53/134—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings monocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/26—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C61/12—Saturated polycyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C61/16—Unsaturated compounds
- C07C61/28—Unsaturated compounds polycyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C61/16—Unsaturated compounds
- C07C61/35—Unsaturated compounds having unsaturation outside the rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPR2157A AUPR215700A0 (en) | 2000-12-19 | 2000-12-19 | Carboxylic acid compound having cyclopropane ring |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE329894T1 true ATE329894T1 (de) | 2006-07-15 |
Family
ID=3826191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01271349T ATE329894T1 (de) | 2000-12-19 | 2001-12-18 | Verwendung von cyclopropancyclus enthaltenden carbonsäureverbindungen als medikament |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7468389B2 (de) |
| EP (1) | EP1343746B1 (de) |
| JP (1) | JP4212894B2 (de) |
| AT (1) | ATE329894T1 (de) |
| AU (1) | AUPR215700A0 (de) |
| DE (1) | DE60120752T2 (de) |
| WO (1) | WO2002050013A1 (de) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002254029A1 (en) | 2001-02-27 | 2002-09-12 | Daniel L. Alkon | Alzheimer's disease diagnosis based on mitogen-activated protein kinase phosphorylation |
| US20050065205A1 (en) * | 2002-03-07 | 2005-03-24 | Daniel Alkon | Methods for Alzheimer's disease treatment and cognitive enhance |
| US6825229B2 (en) | 2002-03-07 | 2004-11-30 | Blanchette Rockefeller Neurosciences Institute | Methods for Alzheimer's Disease treatment and cognitive enhancement |
| US20080004332A1 (en) * | 2002-03-07 | 2008-01-03 | Alkon Daniel L | Methods for alzheimer's disease treatment and cognitive enhancement |
| DE10254265A1 (de) * | 2002-11-21 | 2004-06-03 | Symrise Gmbh & Co. Kg | 2-Heptylcyclopropyl-1-carbonsäure |
| TW201206425A (en) * | 2004-05-18 | 2012-02-16 | Brni Neurosciences Inst | Treatment of depressive disorders |
| CA2582270A1 (en) * | 2004-11-15 | 2006-05-26 | Blanchette Rockefeller Neurosciences Institute | Abnormalities of phosphatase 2a (pp2a) for diagnosis and treatment of alzheimer's disease |
| US20070054890A1 (en) | 2005-07-29 | 2007-03-08 | Alkon Daniel L | Protein synthesis required for long-term memory is induced by PKC activation on days preceding associative learning |
| US20090029873A1 (en) * | 2005-10-11 | 2009-01-29 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb) |
| JP5317405B2 (ja) * | 2006-10-03 | 2013-10-16 | 知之 西崎 | 脳機能の改善剤及びそのスクリーニング方法 |
| JP2008143819A (ja) * | 2006-12-08 | 2008-06-26 | Tomoyuki Nishizaki | 酸化ストレス誘導細胞死の抑制剤 |
| EP3332797A3 (de) * | 2007-02-09 | 2018-08-01 | Blanchette Rockefeller Neurosciences Institute | Therapeutische wirkungen von bryostatinen, bryologen und anderen damit zusammenhängenden substanzen auf durch kopftraumata herbeigeführte gedächtnisstörungen und hirnverletzungen |
| CA2731171C (en) | 2008-07-28 | 2016-10-18 | Blanchette Rockefeller Neurosciences Institute | Pkc-activating compounds for the treatment of neurodegenerative diseases |
| EP2669386A1 (de) | 2008-07-28 | 2013-12-04 | Blanchette Rockefeller Neurosciences Institute | Stimulierte ausgelöste genomische Profilmarker von Morbus Alzheimer |
| JP5455396B2 (ja) * | 2009-02-27 | 2014-03-26 | 知之 西崎 | プロテインホスファターゼ−１阻害剤 |
| EP2483695A2 (de) * | 2009-10-02 | 2012-08-08 | Blanchette Rockefeller Neurosciences, Institute | Unnormale änderungen der verarbeitung von pkc-isozymen in morbus-alzheimer-peripherzellen |
| EP2483684B1 (de) | 2009-10-02 | 2018-04-18 | Blanchette Rockefeller Neurosciences, Institute | Fibroblast wachstumsmuster zur diagnose der alzheimer-krankheit |
| WO2012067111A1 (ja) * | 2010-11-16 | 2012-05-24 | 株式会社西崎創薬研究所 | ＰＫＣ－ε活性化剤 |
| EP2780316B1 (de) | 2011-11-13 | 2020-04-15 | Blanchette Rockefeller Neurosciences Institute | Ester von dcpla und behandlungsverfahren damit |
| EP2957285B1 (de) | 2013-02-15 | 2018-01-10 | Nishizaki Bioinformation Research Institute | Phospholipidverbindung mit einem ungesättigten fettsäurederivat mit einem cyclopropan-ring |
| EP2959896B1 (de) * | 2013-02-22 | 2020-09-23 | Nishizaki Bioinformation Research Institute | Verwendung von dcp-la als reagenz zur hemmung der protein-tyrosin-phosphatase 1b in vitro |
| EP2982370A4 (de) * | 2013-04-04 | 2016-10-12 | Nishizaki Bioinformation Res Inst | Mittel zur förderung einer elastinsynthese/-regeneration |
| JPWO2014185481A1 (ja) | 2013-05-17 | 2017-02-23 | 株式会社 西崎創薬研究所 | 選択的５−ｈｔ１ａセロトニン受容体の細胞膜輸送促進剤 |
| EP3006033A4 (de) | 2013-06-07 | 2017-01-04 | KTN Biotec, Inc. | Antikrebsmittel |
| WO2015105094A1 (ja) | 2014-01-07 | 2015-07-16 | 株式会社西崎創薬研究所 | 糖尿病治療薬 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL45320A (en) * | 1974-07-22 | 1980-03-31 | Nechama S Kosower | Cyclopropane fatty acids alkoxyalkyl esters and their use as membrane mobility agents in plant and animal cells |
| JPS5795937A (en) | 1980-12-08 | 1982-06-15 | Ono Pharmaceut Co Ltd | Leucotriene a analogous compound, its preparation, and leucotriene biosynthetic inhibitor containing said compound as active constituent |
| US4442099A (en) * | 1981-11-27 | 1984-04-10 | Research Corporation | Leukotriene analogues |
| JPS58194836A (ja) | 1982-05-11 | 1983-11-12 | Sankyo Co Ltd | ５，６−メタノ−ロイコトリエンａ４誘導体 |
| US4562006A (en) * | 1984-01-11 | 1985-12-31 | Warner-Lambert Company | Cycloheptadiene derivatives |
| US5716929A (en) * | 1994-06-17 | 1998-02-10 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| GB9514448D0 (en) * | 1995-07-14 | 1995-09-13 | Iaf Biochem Int | Novel heterocyclic NMDA-receptor antagonists |
| US6310060B1 (en) | 1998-06-24 | 2001-10-30 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
| US6169103B1 (en) * | 1998-03-03 | 2001-01-02 | Warner-Lambert | Fluorine-substituted biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases |
| JPH11299285A (ja) * | 1998-04-16 | 1999-10-29 | Fanuc Ltd | サーボアンプ |
| NZ525513A (en) * | 1998-08-07 | 2004-09-24 | Pont Pharmaceuticals Du | Succinoylamino lactams as inhibitors of Abeta protein production |
| ATE366259T1 (de) * | 1999-03-04 | 2007-07-15 | Praecis Pharm Inc | Beta-amyloid-peptidaggregation regulierende peptide mit d-aminosäuren |
| US6887898B1 (en) * | 1999-10-22 | 2005-05-03 | Darrick S. H. L. Kim | Pharmaceutical compositions useful in prevention and treatment of beta-Amyloid protein-induced disease |
-
2000
- 2000-12-19 AU AUPR2157A patent/AUPR215700A0/en not_active Abandoned
-
2001
- 2001-12-18 US US10/450,816 patent/US7468389B2/en not_active Expired - Lifetime
- 2001-12-18 AT AT01271349T patent/ATE329894T1/de not_active IP Right Cessation
- 2001-12-18 JP JP2002551514A patent/JP4212894B2/ja not_active Expired - Fee Related
- 2001-12-18 EP EP01271349A patent/EP1343746B1/de not_active Expired - Lifetime
- 2001-12-18 WO PCT/JP2001/011066 patent/WO2002050013A1/en not_active Ceased
- 2001-12-18 DE DE60120752T patent/DE60120752T2/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004516277A (ja) | 2004-06-03 |
| DE60120752D1 (de) | 2006-07-27 |
| JP4212894B2 (ja) | 2009-01-21 |
| AUPR215700A0 (en) | 2001-01-25 |
| EP1343746A1 (de) | 2003-09-17 |
| EP1343746B1 (de) | 2006-06-14 |
| US7468389B2 (en) | 2008-12-23 |
| DE60120752T2 (de) | 2006-10-12 |
| WO2002050013A1 (en) | 2002-06-27 |
| US20050075393A1 (en) | 2005-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE329894T1 (de) | Verwendung von cyclopropancyclus enthaltenden carbonsäureverbindungen als medikament | |
| ES2102132T3 (es) | Amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos. | |
| ATE167476T1 (de) | Substituierte 2-phenyl-3-methocypropensäurenester als fungizide mittel. | |
| ATE71372T1 (de) | Benzothiazol-derivat und es als aktiven bestandteil enthaltendes antirheumatisches mittel. | |
| DE69613365D1 (de) | Ester der 5-aminolevulinsäure als mittel zur photosensibilisierung in der chemotherapie | |
| DK0574313T3 (da) | 1,4-disubstituerede piperaziner til behandling af sygdomme i centralnervesystemet og neuroendocrine sygdomme | |
| DE69229442D1 (de) | Substituierte dibenzooxazepin-verbindungen, pharmazeutische zusammensetzungen und verfahren zur verwendung | |
| ATE196141T1 (de) | Heterocyclisch substituierte phenyl-cyclohexan- carbonsäurederivate als angiotensin ii antagonisten | |
| DE59608698D1 (de) | Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden, enthaltend Sympthomimeticum und Pantothenol und/oder Pantothensäure | |
| ATE206926T1 (de) | Verwendung eines phosphorsäurediesters zur herstellung eines arzneimittels zur behandlung von akne | |
| ATE345344T1 (de) | (oxopyrazolo 1,5aöpyrimidin-2-yl) alkylcarbonsäureamide | |
| NO971743L (no) | Farmasöytisk sammensetning for profylakse og behandling av type I allergiske sykdommer | |
| EP0446921A3 (en) | Optically active alkylene-dioxybenzene derivatives and their use in therapy | |
| FI923662A0 (fi) | Terapeutiska medel. | |
| AR013538A1 (es) | Nuevos mitogenos especificos de osteoblastos, metodos para prepararlos y drogas que contienen tales compuestos | |
| ATE134876T1 (de) | Ein flurbiprofen enthaltendes retard-arzneimittel und seine verwendung | |
| DK1633374T3 (da) | Sammensætning af alkandicarboxylsyrer og et farmaceutisk aktivt stof | |
| DE3864209D1 (de) | Pharmazeutische verwendung aromatischer thioaether. | |
| ATE464063T1 (de) | Topisch applizierbare kosmetische oder pharmazeutische zusammensetzung zur prävention oder behandlung androgener alopezie | |
| TH21523A (th) | 2,8-ไตซับสทิทิวเทคควิราโซลิโนน | |
| IT1229846B (it) | Esteri di catecolammine. | |
| DE59804682D1 (de) | Leukotrien-b4 derivate, insbesondere oximo-ltb4 antagonisten | |
| DK0600085T3 (de) | ||
| SE0201935D0 (sv) | Therapeutic agents | |
| ATE193445T1 (de) | Verwendung des alpha,alpha-diphenylessigsäure-4- (n-methyl-piperidyl)esters als spasmoanalgetikum |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |